Filtered By:
Condition: Diabetes
Management: Marketing

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 27 results found since Jan 2013.

Diet Beverages Linked To Increased Stroke Risk & Heart Attacks
This study, as well as other research on the connection between diet beverages and vascular disease, is observational and cannot show cause and effect. That’s a major limitation, researchers say, as it’s impossible to determine whether the association is due to a specific artificial sweetener, a type of beverage or another hidden health issue. “Postmenopausal women tend to have higher risk for vascular disease because they are lacking the protective effects of natural hormones,” North Carolina cardiologist Dr. Kevin Campbell said, which could contribute to increased risk for heart disease and stroke...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 14, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Heart Attack Stroke Source Type: news

Diet Drinks Linked To Increased Stroke Risk & Heart Attacks
This study, as well as other research on the connection between diet beverages and vascular disease, is observational and cannot show cause and effect. That’s a major limitation, researchers say, as it’s impossible to determine whether the association is due to a specific artificial sweetener, a type of beverage or another hidden health issue. “Postmenopausal women tend to have higher risk for vascular disease because they are lacking the protective effects of natural hormones,” North Carolina cardiologist Dr. Kevin Campbell said, which could contribute to increased risk for heart disease and stroke...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 14, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Heart Attack Stroke Source Type: news

NICE issues final appraisal determination on apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation
Source: NICE Area: News In its final appraisal determination (FAD), NICE has supported the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with one or more risk factors (prior stroke or ischaemic attack, age 75 years or older, hypertension, diabetes mellitus or symptomatic heart failure).   The appeal period for this appraisal will close on 6 February 2013.
Source: NeLM - Cardiovascular Medicine - January 23, 2013 Category: Cardiology Source Type: news

NICE issues final guidance supporting the use of apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE Area: Evidence > Guidelines NICE has issued final guidance (TA 275) supporting the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with 1 or more risk factors such as:   . prior stroke or transient ischaemic attack . age 75 years or older . hypertension . diabetes mellitus . symptomatic heart failure.   NICE notes that the decision about whether to start treatment with apixaban should be made after an informed discussion between the clinici...
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Making Sense of Nutraceuticals in China
The Chinese nutraceutical market is considered the third largest in the world after the US and Japan, or the fourth largest if Europe is counted as a single market.Despite strong fundamentals and high rates of annual growth, though, the Chinese market remains some way from realizing its true potential. Its evolution is muddied by ambiguities around what nutraceuticals actually are and how they should be managed.The result has been polarization between over-zealous regulation of so-called health foods, and a grey market where products have skirted approval procedures through questionable positioning or by exploiting alterna...
Source: EyeForPharma - February 10, 2017 Category: Pharmaceuticals Authors: Marc Yates Source Type: news

FDA approves alogliptin for type 2 diabetes as three separate preparations
Source: FDA Area: News The FDA has approved alogliptin for the treatment of type 2 diabetes as three separate preparations: alogliptin monotherapy; alogliptin in combination with metformin; and alogliptin in combination with pioglitazone.   Alogliptin stimulates insulin release following meals and was shown to be safe and effective as monotherapy in 14 clinical trials involving approximately 8,500 patients with type 2 diabetes.  Alogliptin monotherapy reduced glycosylated haemoglobin (HBA1c) by 0.4 to 0.6% compared to placebo following 26 weeks of treatment.   The FDA has requested additional data ...
Source: NeLM - News - January 28, 2013 Category: Drugs & Pharmacology Source Type: news

Families face battle with GSK over dangerous diabetes drug
Exclusive: Pharmaceutical giant resists claims despite settlement with victims in USThousands of families in the UK could be deprived of compensation for the death or harm of a relative caused by the diabetes drug Avandia, even though the British maker has agreed to pay billions of dollars to settle similar claims in the US.The licence for Avandia was revoked in Europe, in September 2010, because of evidence that it could cause heart failure and heart attacks. The drug can still be prescribed in the US, but not to patients at risk of heart problems.A scientist with the Food and Drug Administration estimated that Avandia co...
Source: Guardian Unlimited Science - January 29, 2013 Category: Science Authors: Sarah Boseley Tags: The Guardian United States World news Pharmaceuticals industry Medical research Legal aid Law UK news Diabetes GlaxoSmithKline Business Source Type: news

OPINION: Now Is the Time to Tackle Malnutrition and Its Massive Human Costs
Sadhana Ghimire, 23, makes sure to give her 18-month-old daughter nutritious food, such as porridge containing grains and pulses, in order to prevent stunting. Credit: Mallika Aryal/IPSBy José Graziano da Silva and Margaret ChanROME/GENEVA, Nov 13 2014 (IPS)The scourge of malnutrition affects the most vulnerable in society, and it hurts most in the earliest stages of life. Today, more than 800 million people are chronically hungry, about 11 percent of the global population.Undernutrition is the underlying cause of almost half of all child deaths, and a quarter of living children are stunted due to inadequate nutrition. Mi...
Source: IPS Inter Press Service - Health - November 13, 2014 Category: Global & Universal Authors: Jose Graziano da Silva and Margaret Chan Tags: Advancing Deserts Biodiversity Climate Change Development & Aid Economy & Trade Environment Food & Agriculture Global Global Governance Headlines Health IPS UN: Inside the Glasshouse Population Poverty & MDGs TerraViva United N Source Type: news

McGuire to take reins at Second Sight, Greenberg heads board | Personnel Moves
Second Sight Medical‘s (NSDQ:EYES) newly appointed CEO Will McGuire is set to take the reins starting August 18, the company said. Announced in June, former CEO Dr. Robert Greenberg will become chairman of the board at Second Sight, replacing Alfred Mann who will become chairman emeritus, according to the Sylmar, Calif.-based ‘bionic eye’-developing company. “Will brings an immense depth of experience in the life sciences industry that will advance Second Sight’s commercialization of the Argus II retinal prosthesis. After a thorough search process, management and the board of directors are con...
Source: Mass Device - August 13, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Invuity Monteris Medical Personnel Moves Second Sight Medical Products Inc. Volcano Corp. Source Type: news

South Carolina Is FED UP
When asked to speak for a group of third and fourth graders about making "healthy choices," I picked the topic that most children have in common ... sugar! I began our discussion with one simple question. "If your parents came into the room and saw you eating out of the sugar bowl, what would they say?" One young man stated it best. "Are you crazy? Put that spoon down!" "Why would your parents say that?" I asked. Another little girl could barely contain herself. Waving her hand furiously she blurted out, "Because all that sugar is bad for you!" Out of the mouths of babes. When I talk to children, teens or adults,...
Source: Healthy Living - The Huffington Post - September 17, 2015 Category: Consumer Health News Source Type: news

No, Omega 3-Enriched Beef Is Not Necessarily Heart Healthy
Feeding cattle flaxseed or marine algae can raise the omega-3 fatty acid levels in ground beef from 30 milligrams per serving to 200 milligrams per serving, as Kansas State University researchers have found. But do higher levels of omega-3s make red meat significantly healthier?   Not according to Kim Larson, a registered dietitian nutritionist and spokesperson for the Academy of Nutrition and Dietetics. The attempt to make beef look like an important source of omega-3s is essentially a marketing ploy, she said. And despite the fatty acid's reputation as a health ...
Source: Science - The Huffington Post - October 14, 2015 Category: Science Source Type: news

Evolution of Pharmacological Obesity Treatments: Focus on Adverse Side‐Effect Profiles
ABSTRACT Pharmacotherapy directed toward reducing body weight may provide benefits for both curbing obesity and lowering the risk of obesity‐associated co‐morbidities. However, many weight loss medications have been withdrawn from the market due to serious adverse effects. Examples include pulmonary hypertension (aminorex), cardiovascular toxicity, e.g. flenfluramine‐induced valvopathy, stroke (phenylpropanolamine), excess non‐fatal cardiovascular events (sibutramine), and neuro‐psychiatric issues (rimonabant ‐ approved in Europe, but not in the US). This negative experience has helped mold the current drug dev...
Source: Diabetes, Obesity and Metabolism - March 1, 2016 Category: Endocrinology Authors: Andrew J. Krentz, Ken Fujioka, Marcus Hompesch Tags: REVIEW ARTICLE Source Type: research

Public Health and Citizens, Truly United
There are just two problems with the prevailing conception of "public health" -- the public, and health. Neither means what we think it means. For starters, there is no public. The public is an anonymous mass, a statistical conception, nameless, faceless, unknowable, and unlovable. I have made the case before that laboring under this crippling fiction, the potential good that all things "public health" might do is much forestalled. We talk, for instance, about the genuine potential to eliminate up to 80 percent of the total global burden of chronic disease -- heart disease, cancer, stroke, diabetes, dementia -- but somehow...
Source: Healthy Living - The Huffington Post - March 3, 2016 Category: Consumer Health News Source Type: news